NKF 2010 Spring Meetings Coverage
LAS VEGAS—Fibroblast growth factor 23 (FGF-23) is not significantly associated with dietary phosphorus or urinary phosphorus excretion, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.
New approach may ease problems with noncompliance, according to researchers.
Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results
Compared with incident hemodialysis (HD) patients, incident peritoneal dialysis (PD) patients, especially non-diabetics, show a robust and consistent survival advantage for up to five years.
Patients with renal disease who are well prepared to start dialysis are significantly more likely to survive their first year of treatment, according to a study presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.
Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.
Central venous catheters are the most prevalent access type in patients who initiated hemodialysis (HD) following a failed renal transplant.
Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.
Using sevelamer instead of calcium-based binders (CBBs) to treat hyperphosphatemia in dialysis patients can significantly decrease the number of days of hospitalization.
Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.
Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.
Sevelamer carbonate significantly decreases the bioavailability of oral calcitriol when the two drugs are administered together, but lanthanum carbonate does not, show data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
The daily fluid intake with phosphate binder (PB) pills accounts for a significant portion of the daily fluid restriction in hemodialysis (HD) patients, suggest data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)